# US 2025/0152548 A1 · Methods of providing solriamfetol therapy to subjects with impaired renal function

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0152548 A1
- Document ID: US20250152548A1
- Status: Published application
- Kind: A1
- Application number: 19/019,748
- Filed: 2025-01-14
- Published: 2025-05-15
- Earliest claimed: 2020-03-19
- Assignees: Axsome Malta Ltd.
- Applicants: Axsome Malta Ltd.
- Inventors: Katayoun Zomorodi; Herriot Tabuteau
- Web page: https://patentgrep.com/patent/US20250152548A1

## CPC

- A61K 31/325: Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof (thiurams A61K31/145)
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61P 25/26: Psychostimulants, e.g. nicotine, cocaine
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to methods for decreasing adverse effects associated with solriamfetol ([R]-2-amino-3-phenylpropylcarbamate) therapy in subjects with impaired renal function. In particular, the invention provides an optimized dose escalation scheme for subjects with moderate renal impairment which results in the subjects having increased tolerance to adverse effects associated with the administration of solriamfetol. The invention also provides adjusted dosing for safe therapeutic use of solriamfetol in subjects having severe renal impairment.

## Claims

### Claim 1

A method of reducing toxicity due to [R]-2-amino-3-phenylpropylcarbamate (APC), said method comprising selecting a subject having normal renal function ingesting more than a therapeutically effective dose of APC, wherein the APC is the form of a hydrochloride salt, and administering hemodialysis to the subject in a 12 hour session.

### Claim 2 (depends on 1)

The method of claim 1, wherein the APC is cleared from the subject.

### Claim 3 (depends on 1)

The method of claim 1, wherein the subject is being treated for excessive daytime sleepiness.

### Claim 4 (depends on 3)

The method of claim 3, wherein the excessive daytime sleepiness is due to obstructive sleep apnea.

### Claim 5 (depends on 3)

The method of claim 3, wherein the excessive daytime sleepiness is due to narcolepsy.

### Claim 6 (depends on 3)

The method of claim 3, wherein the excessive daytime sleepiness is due to shift work disorder.

### Claim 7 (depends on 1)

The method of claim 1, wherein the subject is being treated for attention deficit hyperactivity disorder.

### Claim 8 (depends on 1)

The method of claim 1, wherein the subject is being treated for binge eating disorder.

### Claim 9 (depends on 1)

The method of claim 1, wherein the therapeutically effective dose is 37.5 mg once daily.

### Claim 10 (depends on 1)

The method of claim 1, wherein the therapeutically effective dose is 75 mg once daily.

### Claim 11 (depends on 1)

The method of claim 1, wherein the therapeutically effective dose is 150 mg once daily.

### Claim 12 (depends on 1)

The method of claim 1, wherein the therapeutically effective dose is 300 mg once daily.

### Claim 13 (depends on 1)

The method of claim 1, wherein the subject is treated concurrently with a monoamine oxidase inhibitor (MAOI) or was treated with an MAOI within the preceding 14 days.
